Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia; St Vincent's Hospital Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia.
St Vincent's Hospital Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne VIC 3000, Australia.
Oral Oncol. 2022 Oct;133:106052. doi: 10.1016/j.oraloncology.2022.106052. Epub 2022 Jul 31.
Carcinoma ex Pleomorphic Adenoma (CXPA) is a rare primary salivary gland malignancy, typically arising from a pre-existing pleomorphic adenoma. This systematic review examines prognostic factors affecting overall survival (OS) in major and minor salivary gland CXPA.
Systematic review of MEDLINE, Cochrane, Scopus, Web of Science, CINAHL, and Open Grey databases from inception to 31st March 2022 for all English-language literature pertaining to 'carcinoma ex pleomorphic adenoma'. All study types with greater than five patients with CXPA of the major and minor salivary glands were eligible for inclusion.
Of 8143 studies, 39 studies (n = 5637 patients) meeting the inclusion criteria were included. Median OS at one, three, five, and ten years were 90.0 %, 72.0 %, 61.9 %, and 45.0 % respectively for all CXPA. Higher staging, T stage, nodal disease, grading, and invasion ≥ 1.5 mm had worse outcomes. Histological subtype, perineural invasion, and radiotherapy did not demonstrate a consistent trend. Three studies were evaluated to have high risk of bias, and was removed for sensitivity analysis.
Survival outcomes worsen with time for all salivary gland CXPA. Further research on histopathological features and the utility of radiation therapy is required to guide patient selection for more aggressive treatment.
CRD42021238544 (PROSPERO).
癌在多形性腺瘤(CXPA)是一种罕见的原发性涎腺癌,通常起源于先前存在的多形性腺瘤。本系统评价检查了影响大、小涎腺 CXPA 总生存率(OS)的预后因素。
对 MEDLINE、Cochrane、Scopus、Web of Science、CINAHL 和 Open Grey 数据库进行了系统评价,检索时间从建库至 2022 年 3 月 31 日,检索内容为所有与“癌在多形性腺瘤”相关的英文文献。所有研究类型均纳入了大、小涎腺 CXPA 患者 5 例以上的研究。
在 8143 项研究中,符合纳入标准的 39 项研究(n=5637 例患者)被纳入。所有 CXPA 的 1 年、3 年、5 年和 10 年 OS 中位数分别为 90.0%、72.0%、61.9%和 45.0%。较高的分期、T 分期、淋巴结疾病、分级和侵袭性≥1.5mm 均提示预后较差。组织学亚型、神经周围侵犯和放疗并未表现出一致的趋势。有 3 项研究被评估为存在高偏倚风险,因此在敏感性分析中被剔除。
对于所有涎腺 CXPA,随着时间的推移,生存结果会恶化。需要进一步研究组织病理学特征和放疗的作用,以指导选择更积极的治疗方法。
CRD42021238544(PROSPERO)。